Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SemenGlutide
2026-527538-29-00Phase 2Authorised
- Sponsor
- Capital Region of Denmark
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in male infertility and Overweight comparing Semaglutide with Placebo (2 arms). Primary endpoint: Difference in sperm production at day 200. Planned start Sep 2026; status: authorised.
02
Drugs
03
Conditions
male infertilityOverweight
Beyond the preview
Go deeper on 2026-527538-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527538-29-00.